SCHEMBL13313397

SCHEMBL13313397

COc1nc(OCc2ccccc2)c2nc(Cl)ccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
MAT2A P31153 1/20 0.39
HRH4 Q9H3N8 2/20 0.38
PDE5A O76074 1/20 0.38
MPO P05164 2/20 0.38
HPGD P15428 2/20 0.38
TPO P07202 1/20 0.38
CYP3A4 P08684 1/20 0.38
EPX P11678 1/20 0.38
MGMT P16455 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
PIN1 Q13526 1/20 0.37
PRMT5 O14744 1/20 0.37
HTT P42858 3/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13313393 0.87 L3MBTL1 (0.43) L3MBTL1HRH4PDE5AMPOTPO
SCHEMBL13313396 0.85 L3MBTL1 (0.48) L3MBTL1HRH4PDE5AMPOTPO
SCHEMBL13313402 0.81 L3MBTL1 (0.49) L3MBTL1HRH4PDE5AMPOHPGD
SCHEMBL13348652 0.78 MAT2A (0.35) L3MBTL1MAT2AHPGDCYP3A4KDM4E
SCHEMBL13313413 0.76 MCL1 (0.43) L3MBTL1HRH4MPOHPGDTPO
SCHEMBL4102997 0.76 ACHE (0.45) L3MBTL1MPOSMN1; SMN2
SCHEMBL24461269 0.75 L3MBTL1 (0.46) L3MBTL1HPGDKDM4EPDGFRBPDGFRA
SCHEMBL32688297 0.71 MAOB (0.44) L3MBTL1PDGFRBPDGFRAPIN1HTT
SCHEMBL7499766 0.69 ALDH1A1 (0.51) L3MBTL1PDE5AHPGDCYP3A4KDM4E
SCHEMBL13313401 0.69 L3MBTL1 (0.48) L3MBTL1HRH4PDE5AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 L3MBTL1 2272/4885MAT2A 3310/4885HRH4 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.